The degradation of many intracellular short‐lived proteins relies on the ubiquitin‐proteasome system (UPS).56 The therapy targeting the ubiquitin system has developed into a promising strategy for cancer treatment.57 Data from our patient samples together with analyses of multiple independent datasets show that higher USP33 expression is significantly associated with longer patient survival, suggesting the potential applications of USP33 for GC therapy and predicting prognosis. This evidence concerns the gene USP33 and cancer.